Valion Bio Inc Financials
This page shows Valion Bio Inc (VBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Valion Bio Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Valion Bio Inc carries a low D/E ratio of 0.88, meaning only $0.88 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 84/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 20.13, Valion Bio Inc holds $20.13 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Valion Bio Inc generates a -52.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -223.1% the prior year.
Valion Bio Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Valion Bio Inc generates $0.79 in operating cash flow (-$7.0M OCF vs -$8.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Valion Bio Inc earns $-54.1 in operating income for every $1 of interest expense (-$7.9M vs $146K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Valion Bio Inc's EBITDA was -$7.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 76.5% from the prior year.
Valion Bio Inc reported -$8.9M in net income in fiscal year 2025. This represents a decrease of 57.0% from the prior year.
Cash & Balance Sheet
Valion Bio Inc generated -$7.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 22.9% from the prior year.
Valion Bio Inc held $12.6M in cash against $0 in long-term debt as of fiscal year 2025.
Valion Bio Inc had 3M shares outstanding in fiscal year 2025. This represents an increase of 353.5% from the prior year.
Margins & Returns
Valion Bio Inc's ROE was -52.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 170.2 percentage points from the prior year.
Capital Allocation
Valion Bio Inc invested $3.1M in research and development in fiscal year 2025. This represents an increase of 138.5% from the prior year.
Valion Bio Inc invested $38K in capex in fiscal year 2025, funding long-term assets and infrastructure.
VBIO Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $146K+69.8% | $86K+22.9% | $70K-61.1% | $180K+42.9% | $126K-10.0% | $140K |
| Cost of Revenue | N/A | N/A | $291K+809.4% | $32K+60.0% | $20K-95.2% | $419K+411.0% | $82K-25.5% | $110K |
| Gross Profit | N/A | N/A | -$145K-368.5% | $54K+8.0% | $50K+120.9% | -$239K-643.2% | $44K+46.7% | $30K |
| R&D Expenses | $1.9M | N/A | $858K+31.0% | $655K+95.5% | $335K+0.6% | $333K-21.1% | $422K+39.7% | $302K |
| SG&A Expenses | $3.8M | N/A | $1.1M+17.4% | $907K-13.0% | $1.0M+55.5% | $670K-18.2% | $819K+4.1% | $787K |
| Operating Income | -$5.6M | N/A | -$2.5M-28.4% | -$1.9M-40.5% | -$1.4M-362.1% | -$298K+79.2% | -$1.4M-13.0% | -$1.3M |
| Interest Expense | $648K | N/A | N/A | $3K | $0 | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$6.2M | N/A | -$2.6M-34.4% | -$1.9M-28.6% | -$1.5M-1.7% | -$1.5M-3.2% | -$1.4M-13.0% | -$1.3M |
| EPS (Diluted) | N/A | N/A | N/A | $-2.19+13.1% | $-2.52 | N/A | $-0.23+95.7% | $-5.37 |
VBIO Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $38.2M+20.9% | $31.6M+407.4% | $6.2M+38.2% | $4.5M+19.4% | $3.8M+34.6% | $2.8M-17.3% | $3.4M-29.0% | $4.8M |
| Current Assets | $8.7M-33.5% | $13.0M+247.8% | $3.7M+103.0% | $1.8M+46.1% | $1.3M-52.2% | $2.6M-16.6% | $3.2M-32.2% | $4.7M |
| Cash & Equivalents | $7.2M-42.9% | $12.6M+266.5% | $3.5M+191.4% | $1.2M+77.0% | $669K-66.6% | $2.0M-8.5% | $2.2M-40.7% | $3.7M |
| Inventory | $750K | $0-100.0% | $4K-98.6% | $283K-7.5% | $306K-4.1% | $319K-56.4% | $731K-4.6% | $766K |
| Accounts Receivable | N/A | N/A | $19K+46.2% | $13K0.0% | $13K-81.2% | $69K+666.7% | $9K-43.8% | $16K |
| Goodwill | $3.5M0.0% | $3.5M | N/A | N/A | N/A | $0 | N/A | N/A |
| Total Liabilities | $19.7M+32.8% | $14.8M+426.1% | $2.8M+242.9% | $821K+10.8% | $741K+172.4% | $272K-51.4% | $560K-5.2% | $591K |
| Current Liabilities | $2.6M+304.8% | $646K+1.3% | $638K-22.3% | $821K+10.8% | $741K+172.4% | $272K-51.4% | $560K-5.2% | $591K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $11.1M-34.1% | $16.8M+392.0% | $3.4M+3.0% | $3.3M+9.1% | $3.0M+19.8% | $2.5M-10.6% | $2.8M-32.4% | $4.2M |
| Retained Earnings | -$59.0M-12.2% | -$52.6M-6.0% | -$49.6M-5.6% | -$47.0M-4.3% | -$45.0M-3.4% | -$43.5M-3.5% | -$42.1M-3.5% | -$40.6M |
VBIO Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.0M-119.1% | -$2.3M-14.6% | -$2.0M-9.3% | -$1.8M-105.5% | -$889K+34.9% | -$1.4M+3.0% | -$1.4M-9.3% | -$1.3M |
| Capital Expenditures | $7K-72.0% | $25K+150.0% | $10K+233.3% | $3K | $0 | $0 | N/A | N/A |
| Free Cash Flow | -$5.0M-117.0% | -$2.3M-15.3% | -$2.0M-9.6% | -$1.8M-105.8% | -$889K+34.9% | -$1.4M | N/A | N/A |
| Investing Cash Flow | -$7K+95.3% | -$149K-1390.0% | -$10K+50.0% | -$20K+96.2% | -$526K | $0 | N/A | N/A |
| Financing Cash Flow | -$44K-100.4% | $11.6M+172.3% | $4.3M+80.9% | $2.4M+2780.5% | $82K-93.0% | $1.2M+1314.4% | -$97K-102.9% | $3.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VBIO Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | -99.3%-162.1pp | 62.8%-8.6pp | 71.4%+204.2pp | -132.8%-167.7pp | 34.9%+13.5pp | 21.4% |
| Operating Margin | N/A | N/A | -1700.7%+548.2pp | -2248.8%-281.7pp | -1967.1%-1801.6pp | -165.6%+970.2pp | -1135.7%-231.4pp | -904.3% |
| Net Margin | N/A | N/A | -1778.1%+467.3pp | -2245.3%-99.6pp | -2145.7%-1325.2pp | -820.6%+315.2pp | -1135.7%-231.4pp | -904.3% |
| Return on Equity | -56.1% | N/A | -76.0%-17.8pp | -58.3%-8.8pp | -49.5%+8.8pp | -58.3%-7.8pp | -50.5%-20.3pp | -30.2% |
| Return on Assets | -16.2% | N/A | -41.7%+1.2pp | -42.8%-3.1pp | -39.8%+12.8pp | -52.6%-10.5pp | -42.2%-15.7pp | -26.5% |
| Current Ratio | 3.31-16.8 | 20.13+14.3 | 5.86+3.6 | 2.24+0.5 | 1.70-8.0 | 9.70+4.1 | 5.65-2.2 | 7.89 |
| Debt-to-Equity | 1.78+0.9 | 0.88+0.1 | 0.82+0.6 | 0.250.0 | 0.24+0.1 | 0.11-0.1 | 0.20+0.1 | 0.14 |
| FCF Margin | N/A | N/A | -1374.0%+753.9pp | -2127.9%-857.9pp | -1270.0%-511.7pp | -758.3% | N/A | N/A |
Frequently Asked Questions
Is Valion Bio Inc profitable?
No, Valion Bio Inc (VBIO) reported a net income of -$8.9M in fiscal year 2025.
What is Valion Bio Inc's EBITDA?
Valion Bio Inc (VBIO) had EBITDA of -$7.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Valion Bio Inc's return on equity (ROE)?
Valion Bio Inc (VBIO) has a return on equity of -52.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Valion Bio Inc's free cash flow?
Valion Bio Inc (VBIO) generated -$7.0M in free cash flow during fiscal year 2025. This represents a -22.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Valion Bio Inc's operating cash flow?
Valion Bio Inc (VBIO) generated -$7.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Valion Bio Inc's total assets?
Valion Bio Inc (VBIO) had $31.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Valion Bio Inc's capital expenditures?
Valion Bio Inc (VBIO) invested $38K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Valion Bio Inc spend on research and development?
Valion Bio Inc (VBIO) invested $3.1M in research and development during fiscal year 2025.
What is Valion Bio Inc's current ratio?
Valion Bio Inc (VBIO) had a current ratio of 20.13 as of fiscal year 2025, which is generally considered healthy.
What is Valion Bio Inc's debt-to-equity ratio?
Valion Bio Inc (VBIO) had a debt-to-equity ratio of 0.88 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Valion Bio Inc's return on assets (ROA)?
Valion Bio Inc (VBIO) had a return on assets of -28.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Valion Bio Inc's cash runway?
Based on fiscal year 2025 data, Valion Bio Inc (VBIO) had $12.6M in cash against an annual operating cash burn of $7.0M. This gives an estimated cash runway of approximately 22 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Valion Bio Inc's Piotroski F-Score?
Valion Bio Inc (VBIO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Valion Bio Inc's earnings high quality?
Valion Bio Inc (VBIO) has an earnings quality ratio of 0.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Valion Bio Inc cover its interest payments?
Valion Bio Inc (VBIO) has an interest coverage ratio of -54.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Valion Bio Inc?
Valion Bio Inc (VBIO) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.